Monica A. Slavin

Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.

Emerging opportunistic yeast infections in haematology patients.

A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation.

Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response.

Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk.

Surveillance for catheter-associated bloodstream infection in hematology units: quantifying the characteristics of a practical case definition.

Bloodstream infections in haematology: risks and new challenges for prevention.

Risk-based antifungal prophylaxis in hematologic malignancy and stem cell transplantation.

Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death.

Toxoplasmosis and allogeneic stem cell transplantation: can we do better?

Fluoroquinolone prophylaxis: a word of caution.

Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment.

Anaerobes: not to be forgotten in neutropenic fever.

Opportunistic fungal infections in the Asia-Pacific region.

Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.

A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment.

Staphylococcus aureus meningitis: barriers to treatment.

Complications of sepsis: the role of risk prediction rules, biomarkers and host genetics.

Cryptococcosis, lymphoproliferative disorders and modern day chemotherapy regimens.

Fluoroquinolone prophylaxis: worth the cost?

Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.

Relationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients.

More than a feeling: new approach required for assessing immunosuppression.

The prevention and management of infections due to multidrug resistant organisms in haematology patients.

Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection.

Molecular diagnosis of Pneumocystis jirovecii in patients with malignancy: clinical significance of quantitative polymerase chain reaction.

Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis.

Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies.

A different kind of "allogeneic transplant": successful fecal microbiota transplant for recurrent and refractory Clostridium difficile infection in a patient with relapsed aggressive B-cell lymphoma.

Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies.

Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia.

Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital.

Candida glabrata fungaemia at an Australian cancer centre: epidemiology, risk factors and therapy.

The impact of antimicrobial allergy labels on antimicrobial usage in cancer patients.

Improving the outcome of bloodstream infection in patients with hematological malignancies: looking beyond antibiotics.

Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy.

Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing.

Epidemiology of invasive fungal disease in lymphoproliferative disorders.

Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization.

Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit.

Isavuconazole: a role for the newest broad-spectrum triazole.

Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies.

Aseptic technique for accessing central venous catheters: applying a standardised tool to audit 'scrub the hub' practices.

Invasive fungal infections in ALL: a new 'growth' area.

Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.

Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations.

Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.

The epidemiology of Clostridium difficile infection in patients with cancer.

Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field.

Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy.

Improving Antimicrobial Stewardship by Antibiotic Allergy Delabeling: Evaluation of Knowledge, Attitude, and Practices Throughout the Emerging Infections Network.

Risks factors and outcomes of Clostridium difficile infection in patients with cancer: a matched case-control study.

Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes.

Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology.

Clinical effectiveness of early posaconazole suspension pre-emptive therapy in lung transplant recipients: The Alfred's experience.

Influenza vaccination responses: Evaluating impact of repeat vaccination among health care workers.

Impact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicenter Evaluation.

Cart before the horse: use of Aspergillus PCR to increase the diagnostic yield from BAL in hematological patients at risk of invasive aspergillosis.

Predicting Infectious ComplicatioNs in Children with Cancer: an external validation study.

Ibrutinib may impair serological responses to influenza vaccination.

The 3 Cs of Antibiotic Allergy-Classification, Cross-Reactivity, and Collaboration.

External Validation of Six Pediatric Fever and Neutropenia Clinical Decision Rules.

Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre.

Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling.

The Combined Utility of Ex vivo IFN-γ Release Enzyme-Linked ImmunoSpot Assay and In vivo Skin Testing in Patients With Antibiotic-Associated Severe Cutaneous Adverse Reactions.

Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.

Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations.